Home > Insider Trading > Filing (0001567619-20-008620)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1048477	Biomarin Pharmaceutical Inc	BMRN	Pharmaceutical Preparations (2834)	680397820

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1221590	Jacques Jean Bienaime	C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-04-27	20,000	$21.51	318,213	No	4	M	Direct
Common Stock	Disposition	2020-04-27	20,000	$97.73	298,213	No	4	S	Direct
Common Stock	Acquisiton	2020-04-28	20,000	$21.51	318,213	No	4	M	Direct
Common Stock	Disposition	2020-04-28	20,000	$97.58	298,213	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy Common Stock)	Disposition	2020-04-27	20,000	$0.00	20,000	$21.51
Common Stock	Stock Option (Right to buy Common Stock)	Disposition	2020-04-28	20,000	$0.00	20,000	$21.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
49,000	2010-11-12	2020-05-11	No	4	M	Direct
29,000	2010-11-12	2020-05-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	247,958	Indirect	Shares held by Jean-Jacques Bienaime Family Trust

Footnotes

Trade made pursuant to a 10b5-1 plan executed on November 13, 2019.
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 10 shares, with the reporting person's purchase of shares at a price of $75.3786 on November 11, 2019. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 30 shares, with the reporting person's purchase of shares at a price of $94.39 on March 3, 2020. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
Reflects the number of options outstanding after the transactions from this specific stock option grant.